ICON Launches Firecrest Patient Portal to Enhance Education around Informed Consent
17 Junho 2015 - 12:00PM
Business Wire
New Firecrest Patient Portal, part of ICONIK Informatics Hub,
designed to enhance patient engagement and support patient
recruitment and retention.
ICON plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and
medical device industries, today announced the launch of the
Firecrest Patient Portal. This portal enables patients to view
clinical trial information and is specifically designed to enhance
the patients understanding of treatment before consenting to
participate at an investigator site.
The Patient Portal solution is a component of ICON’s new
informatics hub designed to enhance the engagement of patient
populations in the development process and is line with ICH E6
guidance, which recommends patients receive ‘ample time’ to review
consent materials and ask follow-up questions.
“The opportunity for education about the trial, before a
face-to-face meeting with their doctor, helps patients make truly
informed decisions about participation,” said Frances Abeton, Vice
President, Firecrest at ICON plc. “Improved patient comprehension
of a trial can reflect positively in patients’ relationships with
investigators and subsequently lead to better recruitment and
retention rates. As drug developers begin adopting electronic
informed consent platforms improved regulatory-compliant education
will be crucial. The Firecrest Patient Portal is a centralised
solution for patients, investigators and study staff, making it
easier for all involved to interact and stay informed.” said
Abeton.
Patients using the Firecrest Patient Portal can find active
trials, complete pre-screening questionnaires and select a
convenient study location. As the Patient Portal is integrated with
ICON’s Firecrest Investigator Portal, investigators can engage
directly with patients that have shown interest, schedule visits,
and examine live analytics about the materials reviewed by a
patient. Patients can read visit-by-visit guides and as the trial
progresses, patients can return to the portal to review updates or
notifications specific to them. They will also be able to register
interest in future clinical trials that will support patient access
for upcoming trials.
The Firecrest Patient Portal can be customised in any language,
adapted to country specific requirements, and branded as required
by sponsors.
Request a demonstration of Firecrest Patient Portal and learn
more about ICON’s Firecrest solution at
www.iconplc.com/technology/firecrest.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 81 locations in 38 countries and has approximately
11,200 employees. Further information is available at
www.iconplc.com.
More information about ICON’s Firecrest solutions is available
at: www.iconplc.com/technology/firecrest/.
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150617005939/en/
ICON Media ContactRosie IrelandWeber ShandwickTel: +44
(0) 207 067 0190Email: rireland@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024